All News

Patient Access & Engagement

IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
22 November 2023
IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
IN8bio, Inc. has presented compelling
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
16 November 2023
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
The First regulatory authorization of
Phacilitate Announces Lifetime Achievement Award Winner for 2024, and Opens Entries for the Second Advanced Therapies Awards 
13 September 2023
Phacilitate Announces Lifetime Achievement Award Winner for 2024, and Opens Entries for the Second Advanced Therapies Awards 
Following a show-stopping and emotional
The Genesis and Implementation of Labeling Standards to Ensure Patient Safety for CGT Therapies
7 September 2023
The Genesis and Implementation of Labeling Standards to Ensure Patient Safety for CGT Therapies
POPULAR NEWS ITEMS
Image
4 December 2023

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image
6 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image
5 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Structured Debate: The Cost on a Cure – Do the Results Justify the Price?
7 September 2023
Structured Debate: The Cost on a Cure – Do the Results Justify the Price?
Beam Therapeutics Announced First Patient Dosed in Phase I/II Trial in Relapsed, Refractory T-ALL/T-LL
6 September 2023
Beam Therapeutics Announced First Patient Dosed in Phase I/II Trial in Relapsed, Refractory T-ALL/T-LL
Beam Therapeutics Announced First Patient
uniQure Announces FDA Clearance of INDA for Epilepsy Gene Therapy
5 September 2023
uniQure Announces FDA Clearance of INDA for Epilepsy Gene Therapy
uniQure Announces FDA Clearance of
First Person in Europe Commercially Treated with BioMarin’s ROCTAVIAN® for Severe Hemophilia A
31 August 2023
First Person in Europe Commercially Treated with BioMarin’s ROCTAVIAN® for Severe Hemophilia A
BioMarin's ROCTAVIAN gene therapy has
Load more News
RECOMENDED TOPICS
Clinical Trials
Collaborations, Mergers & Acquisitions
Finance & Investment
Patient Access & Engagement
Regulatory & Standards
Reimbursement
Strategy
POPULAR NEWS ITEMS
Image

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome